JP2020504107A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504107A5 JP2020504107A5 JP2019533052A JP2019533052A JP2020504107A5 JP 2020504107 A5 JP2020504107 A5 JP 2020504107A5 JP 2019533052 A JP2019533052 A JP 2019533052A JP 2019533052 A JP2019533052 A JP 2019533052A JP 2020504107 A5 JP2020504107 A5 JP 2020504107A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- purin
- triazolo
- dihydro
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- YPDSIEMYVQERLJ-UHFFFAOYSA-N 8-Hydroxypurine Chemical compound C1=NC=C2NC(O)=NC2=N1 YPDSIEMYVQERLJ-UHFFFAOYSA-N 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 3
- XGWVDWGXBYRXIX-UHFFFAOYSA-N 9-(4-hydroxycyclohexyl)-7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]purin-8-one Chemical compound Cc1cc2ncnn2cc1Nc1ncc2n(C)c(=O)n(C3CCC(O)CC3)c2n1 XGWVDWGXBYRXIX-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- BKWJAKQVGHWELA-UHFFFAOYSA-N 1-[6-(2-hydroxypropan-2-yl)-2-pyridinyl]-6-[4-(4-methyl-1-piperazinyl)anilino]-2-prop-2-enyl-3-pyrazolo[3,4-d]pyrimidinone Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N(CC=C)N(C=3N=C(C=CC=3)C(C)(C)O)C2=N1 BKWJAKQVGHWELA-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- VQSZIPCGAGVRRP-UHFFFAOYSA-N 7-fluoro-3-methyl-8-[6-(3-piperidin-1-ylpropoxy)pyridin-3-yl]-1-propan-2-ylimidazo[4,5-c]quinolin-2-one Chemical compound FC=1C(=CC=2C3=C(C=NC=2C=1)N(C(N3C(C)C)=O)C)C=1C=NC(=CC=1)OCCCN1CCCCC1 VQSZIPCGAGVRRP-UHFFFAOYSA-N 0.000 claims 1
- XISVSTPEXYIKJL-UHFFFAOYSA-N 7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(oxan-4-yl)purin-8-one Chemical compound CN1C(=O)N(C2CCOCC2)C2=NC(NC3=CN4N=CN=C4C=C3C)=NC=C12 XISVSTPEXYIKJL-UHFFFAOYSA-N 0.000 claims 1
- ZXABVFIAHLXSDB-GFCCVEGCSA-N 7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-[(3R)-oxan-3-yl]purin-8-one Chemical compound CN1C(=O)N([C@@H]2CCCOC2)C2=NC(NC3=CN4N=CN=C4C=C3C)=NC=C12 ZXABVFIAHLXSDB-GFCCVEGCSA-N 0.000 claims 1
- ZXABVFIAHLXSDB-LBPRGKRZSA-N 7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-[(3S)-oxan-3-yl]purin-8-one Chemical compound CN1C(=O)N([C@H]2CCCOC2)C2=NC(NC3=CN4N=CN=C4C=C3C)=NC=C12 ZXABVFIAHLXSDB-LBPRGKRZSA-N 0.000 claims 1
- RUHACGHAVPFPAK-NSHDSACASA-N 7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-[(3S)-oxolan-3-yl]purin-8-one Chemical compound CN1C(=O)N([C@H]2CCOC2)C2=NC(NC3=CN4N=CN=C4C=C3C)=NC=C12 RUHACGHAVPFPAK-NSHDSACASA-N 0.000 claims 1
- AOTRIQLYUAFVSC-UHFFFAOYSA-N 8-[6-[3-(dimethylamino)propoxy]pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]quinolin-2-one Chemical compound CN(CCCOC1=CC=C(C=N1)C1=CC=2C3=C(C=NC2C=C1)N(C(N3C3CCOCC3)=O)C)C AOTRIQLYUAFVSC-UHFFFAOYSA-N 0.000 claims 1
- ZFIZVPPSNWVMDU-UHFFFAOYSA-N 9-(4-methoxycyclohexyl)-7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]purin-8-one Chemical compound COC1CCC(CC1)n1c2nc(Nc3cn4ncnc4cc3C)ncc2n(C)c1=O ZFIZVPPSNWVMDU-UHFFFAOYSA-N 0.000 claims 1
- 229940127011 AZD1390 Drugs 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims 1
- 229950009557 adavosertib Drugs 0.000 claims 1
- 229960002550 amrubicin Drugs 0.000 claims 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 1
- 229960002707 bendamustine Drugs 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 229960005243 carmustine Drugs 0.000 claims 1
- OHUHVTCQTUDPIJ-JYCIKRDWSA-N ceralasertib Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 OHUHVTCQTUDPIJ-JYCIKRDWSA-N 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 229960000572 olaparib Drugs 0.000 claims 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 229960001221 pirarubicin Drugs 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 229960000653 valrubicin Drugs 0.000 claims 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436619P | 2016-12-20 | 2016-12-20 | |
| US62/436,619 | 2016-12-20 | ||
| PCT/EP2017/083625 WO2018114999A1 (en) | 2016-12-20 | 2017-12-19 | Amino-triazolopyridine compounds and their use in treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504107A JP2020504107A (ja) | 2020-02-06 |
| JP2020504107A5 true JP2020504107A5 (cg-RX-API-DMAC7.html) | 2020-07-02 |
| JP6883653B2 JP6883653B2 (ja) | 2021-06-09 |
Family
ID=60937727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533052A Active JP6883653B2 (ja) | 2016-12-20 | 2017-12-19 | アミノ−トリアゾロピリジン化合物および癌の治療におけるその使用 |
Country Status (39)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017384388B2 (en) | 2016-12-20 | 2020-09-17 | Astrazeneca Ab | Amino-triazolopyridine compounds and their use in treating cancer |
| TWI820146B (zh) * | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
| WO2020186211A1 (en) * | 2019-03-13 | 2020-09-17 | The Uab Research Foundation | Methods and compositions for treating polyoma virus infection |
| AU2020281332A1 (en) * | 2019-05-27 | 2021-11-04 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Dna-dependent protein kinase inhibitor |
| US20210008161A1 (en) | 2019-06-17 | 2021-01-14 | Crispr Therapeutics Ag | Methods and compositions for improved homology directed repair |
| IL293211A (en) * | 2019-11-22 | 2022-07-01 | Medshine Discovery Inc | Pyrimidopyrrole spiro compounds and derivatives thereof as dna-pk inhibitors |
| CN114728969B (zh) * | 2019-11-25 | 2024-03-08 | 再鼎医药(上海)有限公司 | 作为dna-pk抑制剂的嘧啶并咪唑类化合物 |
| PE20221324A1 (es) | 2019-11-26 | 2022-09-09 | Primmune Therapeutics Inc | Agonistas del tlr7 |
| CN113121573A (zh) * | 2019-12-31 | 2021-07-16 | 成都百裕制药股份有限公司 | 嘌呤衍生物及其在医药上的应用 |
| CN113121538B (zh) * | 2019-12-31 | 2023-04-21 | 成都百裕制药股份有限公司 | 呋喃衍生物及其在医药上的应用 |
| CN113121574B (zh) * | 2019-12-31 | 2023-02-17 | 成都百裕制药股份有限公司 | 嘌呤衍生物及其在医药上的用途 |
| CN113493471B (zh) * | 2020-04-03 | 2024-06-11 | 山东轩竹医药科技有限公司 | 杂芳环类激酶抑制剂 |
| JP7498795B2 (ja) * | 2020-04-17 | 2024-06-12 | チェンドゥ バイユー ファーマシューティカル カンパニー リミテッド | イミダゾリジノン誘導体及びその医薬における応用 |
| CN113549092B (zh) * | 2020-04-23 | 2022-10-18 | 山东轩竹医药科技有限公司 | 三并环类激酶抑制剂 |
| AU2021263745A1 (en) | 2020-04-28 | 2022-12-08 | Intellia Therapeutics, Inc. | Methods of in vitro cell delivery |
| WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
| WO2022017368A1 (zh) * | 2020-07-20 | 2022-01-27 | 首药控股(北京)股份有限公司 | Dna-pk选择性抑制剂及其制备方法和用途 |
| US12280049B2 (en) * | 2020-08-04 | 2025-04-22 | Astrazeneca Ab | Methods of delaying pain progression and treating prostate cancer |
| CN114249753A (zh) * | 2020-09-22 | 2022-03-29 | 山东轩竹医药科技有限公司 | 三唑并吡啶类激酶抑制剂 |
| WO2022064430A1 (en) * | 2020-09-24 | 2022-03-31 | Auckland Uniservices Limited | Novel aminopyridines and their use in treating cancer |
| CN114573605A (zh) * | 2020-12-01 | 2022-06-03 | 武汉光谷亚太医药研究院有限公司 | Dna依赖蛋白激酶抑制剂及其应用 |
| CN114634522A (zh) * | 2020-12-15 | 2022-06-17 | 江苏恒瑞医药股份有限公司 | 嘌呤酮衍生物、其制备方法及其在医药上的应用 |
| AU2021400745A1 (en) | 2020-12-17 | 2023-07-20 | Vertex Pharmaceuticals Incorporated | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
| WO2022135360A1 (zh) * | 2020-12-21 | 2022-06-30 | 江苏恒瑞医药股份有限公司 | 嘌呤酮衍生物、其制备方法及其在医药上的应用 |
| CN114656487B (zh) * | 2020-12-22 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 稠合嘧啶类化合物、其制备方法及其在医药上的应用 |
| TW202229281A (zh) * | 2020-12-24 | 2022-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 嘌呤酮類化合物、其製備方法及其在醫藥上的應用 |
| WO2022199547A1 (zh) * | 2021-03-22 | 2022-09-29 | 成都赜灵生物医药科技有限公司 | 一种7,9-二氢嘌呤衍生物及其制药用途 |
| MX2023012236A (es) | 2021-04-17 | 2024-01-23 | Intellia Therapeutics Inc | Inhibidores de proteína cinasa dependente de acido desoxirribonucleico (and) y composiciones y usos de los mismos. |
| EP4342899A1 (en) * | 2021-05-19 | 2024-03-27 | Zai Lab (Shanghai) Co., Ltd. | Salt form and crystal form of heterocyclic substituted purinone derivative |
| CN117377676A (zh) * | 2021-06-29 | 2024-01-09 | 成都百裕制药股份有限公司 | 嘌呤衍生物的晶型及其药物组合物 |
| CN116023395B (zh) * | 2021-10-25 | 2025-07-15 | 山东轩竹医药科技有限公司 | 三环类激酶抑制剂的晶型 |
| CN116023393B (zh) * | 2021-10-25 | 2025-08-12 | 山东轩竹医药科技有限公司 | 三环类激酶抑制剂的晶型 |
| CN116023394B (zh) * | 2021-10-25 | 2025-08-12 | 山东轩竹医药科技有限公司 | 三环类激酶抑制剂的晶型 |
| US20250305004A1 (en) * | 2022-05-13 | 2025-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancing gene targeting efficiency in human cells with dna-pk inhibitor treatment |
| IL321260A (en) | 2022-12-06 | 2025-08-01 | Astrazeneca Ab | Polq inhibitors |
| WO2025023957A1 (en) * | 2023-07-21 | 2025-01-30 | Wei Zhong | Substituted 2-amino-9-(3,3-difluoropiperidin-4-yl)-7,9-dihydro-8h-purin-8-one compounds and their use in treating cancer |
| WO2025049481A1 (en) | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025181336A1 (en) | 2024-03-01 | 2025-09-04 | Cellectis Sa | Compositions and methods for hbb-editing in hspc |
| WO2025248119A1 (en) | 2024-05-31 | 2025-12-04 | Astrazeneca Ab | 6-(cyclo)alkoxypurine derivatives useful as polq inhibitors |
| WO2025248117A1 (en) | 2024-05-31 | 2025-12-04 | Astrazeneca Ab | 6-aminopurine derivatives useful as polq inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| JP4471404B2 (ja) | 1996-02-13 | 2010-06-02 | アストラゼネカ ユーケイ リミテッド | Ｖｅｇｆインヒビターとしてのキナゾリン誘導体 |
| KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| JP4895811B2 (ja) | 2003-09-11 | 2012-03-14 | ケミア，インコーポレイテッド | サイトカイン阻害剤 |
| EP1719761A4 (en) | 2004-02-23 | 2007-10-10 | Dainippon Sumitomo Pharma Co | NEW HETEROCYCLIC CONNECTION |
| WO2006074985A1 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US20090023723A1 (en) | 2005-09-21 | 2009-01-22 | Pharmacopeia Drug Discovery, Inc. | Purinone derivatives for treating neurodegenerative diseases |
| EP1948658A1 (en) | 2005-10-13 | 2008-07-30 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as syk inhibitors |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| AU2007257959A1 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| WO2008043031A1 (en) * | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc. | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| MX337906B (es) | 2006-10-19 | 2016-03-28 | Signal Pharm Llc | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. |
| WO2008153207A1 (ja) | 2007-06-15 | 2008-12-18 | Banyu Pharmaceutical Co., Ltd | ビシクロアニリン誘導体 |
| US20110118238A1 (en) | 2007-08-23 | 2011-05-19 | Astrazeneca Ab | 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders |
| WO2009122180A1 (en) | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
| JP2012197231A (ja) | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体 |
| AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| SG183155A1 (en) | 2010-02-03 | 2012-09-27 | Signal Pharm Llc | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors |
| AU2011240735B2 (en) | 2010-04-13 | 2015-01-29 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer |
| UY34032A (es) | 2011-04-21 | 2012-11-30 | Origenis Gmbh | Nuevos inhibidores de quinasa |
| EA034193B1 (ru) | 2011-04-21 | 2020-01-15 | Оригенис Гмбх | Гетероциклические соединения в качестве ингибиторов киназ |
| EP2527344A1 (en) * | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| JP6121658B2 (ja) | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
| PH12014500869A1 (en) | 2011-10-19 | 2014-06-30 | Signal Pharm Llc | Treatment of cancer with tor kinase inhibitors |
| CA2867349A1 (en) | 2012-03-15 | 2013-09-19 | Signal Pharmaceuticals, Llc | Treatment of cancer with tor kinase inhibitors |
| CN102675897B (zh) | 2012-05-18 | 2015-04-29 | 陕西师范大学 | 硫脲/脲芳胺染料及其制备方法和应用 |
| CN103864792B (zh) | 2012-12-12 | 2017-01-18 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的含氮并环类化合物 |
| US20160008356A1 (en) | 2013-02-28 | 2016-01-14 | Signal Pharmaceuticals, Llc | Treatment of cancer with tor kinase inhibitors |
| NO2714752T3 (cg-RX-API-DMAC7.html) | 2014-05-08 | 2018-04-21 | ||
| AU2017384388B2 (en) | 2016-12-20 | 2020-09-17 | Astrazeneca Ab | Amino-triazolopyridine compounds and their use in treating cancer |
-
2017
- 2017-12-19 AU AU2017384388A patent/AU2017384388B2/en active Active
- 2017-12-19 MA MA47079A patent/MA47079B1/fr unknown
- 2017-12-19 MY MYPI2019003492A patent/MY183036A/en unknown
- 2017-12-19 WO PCT/EP2017/083625 patent/WO2018114999A1/en not_active Ceased
- 2017-12-19 MX MX2019007189A patent/MX390535B/es unknown
- 2017-12-19 US US15/846,679 patent/US10407446B2/en active Active
- 2017-12-19 EP EP17825829.9A patent/EP3558997B1/en active Active
- 2017-12-19 ES ES17825829T patent/ES2867274T3/es active Active
- 2017-12-19 UA UAA201907754A patent/UA123032C2/uk unknown
- 2017-12-19 RS RS20210447A patent/RS61701B1/sr unknown
- 2017-12-19 CR CR20190301A patent/CR20190301A/es unknown
- 2017-12-19 JP JP2019533052A patent/JP6883653B2/ja active Active
- 2017-12-19 SM SM20210225T patent/SMT202100225T1/it unknown
- 2017-12-19 BR BR112019012217-6A patent/BR112019012217B1/pt active IP Right Grant
- 2017-12-19 CA CA3046339A patent/CA3046339C/en active Active
- 2017-12-19 PH PH1/2019/501350A patent/PH12019501350B1/en unknown
- 2017-12-19 KR KR1020197021026A patent/KR102220971B1/ko active Active
- 2017-12-19 HU HUE17825829A patent/HUE054548T2/hu unknown
- 2017-12-19 AR ARP170103582A patent/AR110400A1/es active IP Right Grant
- 2017-12-19 HR HRP20210548TT patent/HRP20210548T1/hr unknown
- 2017-12-19 PE PE2019001276A patent/PE20191474A1/es unknown
- 2017-12-19 LT LTEP17825829.9T patent/LT3558997T/lt unknown
- 2017-12-19 JO JOP/2019/0151A patent/JOP20190151B1/ar active
- 2017-12-19 PL PL17825829T patent/PL3558997T3/pl unknown
- 2017-12-19 PT PT178258299T patent/PT3558997T/pt unknown
- 2017-12-19 NZ NZ755222A patent/NZ755222A/en unknown
- 2017-12-19 SI SI201730707T patent/SI3558997T1/sl unknown
- 2017-12-19 DK DK17825829.9T patent/DK3558997T3/da active
- 2017-12-19 CN CN201780078065.XA patent/CN110177791B/zh active Active
- 2017-12-19 EA EA201991399A patent/EA037745B1/ru unknown
- 2017-12-20 TW TW106144799A patent/TWI776835B/zh active
-
2019
- 2019-06-06 IL IL267158A patent/IL267158B/en active IP Right Grant
- 2019-06-17 DO DO2019000168A patent/DOP2019000168A/es unknown
- 2019-06-19 CL CL2019001714A patent/CL2019001714A1/es unknown
- 2019-06-20 EC ECSENADI201944159A patent/ECSP19044159A/es unknown
- 2019-06-20 NI NI201900062A patent/NI201900062A/es unknown
- 2019-07-17 ZA ZA2019/04695A patent/ZA201904695B/en unknown
- 2019-07-19 CO CONC2019/0007810A patent/CO2019007810A2/es unknown
- 2019-07-30 US US16/526,219 patent/US11136340B2/en active Active
-
2021
- 2021-04-27 CY CY20211100360T patent/CY1124239T1/el unknown
- 2021-08-27 US US17/459,049 patent/US11746118B2/en active Active
-
2023
- 2023-07-10 US US18/349,220 patent/US20240124492A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504107A5 (cg-RX-API-DMAC7.html) | ||
| HRP20210548T1 (hr) | Spojevi amino-triazolopiridina i njihova uporaba u liječenju raka | |
| JP7461390B2 (ja) | メニン－ｍｌｌ相互作用の阻害剤 | |
| JP6703583B2 (ja) | 高活性抗新生物薬及び抗増殖剤 | |
| AU2017326006B2 (en) | Inhibitors of the menin-MLL interaction | |
| ES2929415T3 (es) | Compuestos heterocíclicos tricíclicos como activadores de STING | |
| ES2922580T3 (es) | Derivados de N-piridinilacetamida como inhibidores de la ruta de señalización WNT | |
| ES2973442T3 (es) | Moduladores de la vía integrada del estrés | |
| KR101756050B1 (ko) | 톨 유사 수용체 조정제 화합물 | |
| JP2018531226A5 (cg-RX-API-DMAC7.html) | ||
| MX2013003139A (es) | Profarmaco de derivado de carbamoilpiridona policiclica substituida. | |
| CN102241678B (zh) | 含有脂环结构化合物的抗肿瘤作用与应用 | |
| CN109311843A (zh) | 作为PI3Kβ抑制剂的氮杂苯并咪唑衍生物 | |
| CA3005945A1 (en) | Inhibitors of the menin-mll interaction | |
| JP2010535755A (ja) | イミダゾピリジノン | |
| SI3140303T1 (en) | Compounds of imidazo (4,5-c) quinolin-2-one and their use in the treatment of cancer | |
| RS66126B1 (sr) | Makrociklična jedinjenja kao agonisti uboda i njihove metode i upotreba | |
| RU2018120492A (ru) | ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| CN105175410A (zh) | 三嗪类化合物及其制备方法和抗肿瘤应用 | |
| JP2025503422A (ja) | Ｐｄ－ｌ１を標的とするための方法及び組成物 | |
| JP2018534289A5 (cg-RX-API-DMAC7.html) | ||
| RU2022109286A (ru) | Кристаллическая форма гидрата свободного основания лорлатиниба | |
| TWI722080B (zh) | 共結晶、其製造方法及含有共結晶的醫藥 | |
| JP2020514344A5 (cg-RX-API-DMAC7.html) | ||
| TW202304916A (zh) | 吡唑嘧啶化合物及其用途 |